SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for EDAP TMS SA (EDAP) (CIK 0001041934) (FOCL) — Apr 14, 2021

EDAP TMS SA (EDAP) (CIK 0001041934)
Date: April 14, 2021 · CIK: 0001041934 · Accession: 0000000000-21-004490

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-255101

Date
April 13, 2021
Author
Marc Oczachowski
Form
UPLOAD
Company
EDAP TMS SA (EDAP) (CIK 0001041934)

Letter

United States securities and exchange commission logo April 13, 2021 Marc Oczachowski Chief Executive Officer and Chairman EDAP TMS S.A. Parc d'Activitiés la Poudrette-Lamartine 4/6, rue de Dauphiné 69120 Vaulx-en-Velin, France Re:EDAP TMS S.A. Registration Statement on Form S-3 Filed April 7, 2021 File No. 333-255101 Dear Mr. Oczachowski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter E. Devlin, Esq.

Show Raw Text
United States securities and exchange commission logo
April 13, 2021
Marc Oczachowski
Chief Executive Officer and Chairman
EDAP TMS S.A.
Parc d'Activitiés la Poudrette-Lamartine
4/6, rue de Dauphiné
69120 Vaulx-en-Velin, France
Re:EDAP TMS S.A.
Registration Statement on Form S-3
Filed April 7, 2021
File No. 333-255101
Dear Mr. Oczachowski:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Peter E. Devlin, Esq.